Financing the Growth Journey: Accounting Considerations for Life Sciences Companies

Access to capital is fundamental to advancing a life sciences company from research and development through commercialization. The capital structure is rarely limited to a single form of financing and may include preferred equity, simple agreements for future equity (SAFEs), convertible instruments, warrants, debt, royalty monetization, and milestone-based arrangements. Although each instrument addresses a particular liquidity, dilution, or risk-allocation objective, its contractual provisions may have significant consequences for classification, measurement, earnings volatility, and disclosure. 

Evaluating those consequences as part of the structuring process allows management to consider the full financial reporting impact before terms are finalized and helps avoid difficult accounting conclusions. 

Equity and Equity-Linked Financings 

An equity financing analysis often extends beyond recording cash proceeds and shares issued. Preferred stock may require liability, temporary equity, or permanent equity classification depending on its redemption and settlement provisions. Conversion rights, liquidation preferences, participation features, and anti-dilution protections may also affect presentation and valuation. Warrants and other freestanding instruments issued in the same transaction require a separate classification analysis, including an assessment of settlement provisions and potential adjustments to the exercise price or number of shares. When multiple instruments are issued, management may also need to, assess which instruments are freestanding, determine their respective fair values and allocate the proceeds and transaction costs under the applicable accounting model. For private companies, the absence of observable inputs can make this analysis particularly judgmental. 

Down-round and other anti-dilution provisions, if applicable, should be evaluated before a subsequent financing is priced. A lower-priced issuance may reset an exercise or conversion price, increase the number of issuable shares, or trigger protections across several classes of securities. In addition to the potential dilution, the event may require recognition of a deemed dividend or an earnings-per-share adjustment, or it may change the fair value of a liability-classified warrant or derivative. The precise accounting depends on the instrument’s classification and contractual terms. 

SAFEs and Convertible Instruments 

SAFEs require an instrument-specific analysis of the holder’s settlement rights and the events that determine the form and amount of consideration delivered. In practice, many SAFEs do not qualify for equity classification and are accounted for as liabilities measured at fair value, although the conclusion depends on the specific terms. Valuation may require management to identify the possible settlement outcomes, assign and support probabilities to financing, liquidity, dissolution, or other scenarios, and reassess those assumptions at each reporting date. 

Convertible notes may include valuation caps, conversion discounts, redemption provisions, contingent settlement terms, or change-in-control features. These provisions may affect the classification of the host contract or represent embedded derivatives that require bifurcation and recurring fair value measurement.

Maintaining a controlled and complete instrument inventory is critical. Executed agreements, side letters, amendments, approvals, valuation inputs, and accounting conclusions should be linked so the company can substantiate the terms and assumptions in effect at each reporting date and appropriately account for subsequent conversion, modification, or settlement. 

Debt Financings and Complex Provisions 

Debt agreements used by life sciences companies frequently include economics that are not captured by the stated interest rate. Original issue discounts, exit fees, success-based payments, conversion rights, prepayment provisions, revenue participation, milestone-linked payments , and embedded derivatives. Covenant terms, subjective acceleration clauses, and liquidity-related provisions may also affect classification and disclosure. 

When debt and warrants are issued together, the accounting may require determination of the fair value of both instruments and allocation of proceeds on a relative fair value basis, subject to the applicable classification and measurement guidance. The resulting debt discount and allocated issuance costs impact the effective yield and interest expense recognized over the debt term. If a warrant or embedded feature is liability classified, subsequent fair value changes may introduce additional earnings volatility. 

Amendments, waivers, exchanges, and restructurings should be analyzed when negotiated to determine whether they are accounted for as a debt modification, extinguishment, or troubled debt restructuring, where applicable. While current U.S. GAAP provides the applicable guidance, the Financial Accounting Standards Board (FASB) added a project on accounting for changes in debt to its technical agenda in August 2026. Any conclusions reached in connection with this project remain tentative and will not become authoritative until the FASB issues a final Accounting Standards Update.

Collaborative and Contingent Revenue Arrangements

Royalty, milestone, and revenue participation structures may provide capital in exchange for payments tied to an asset, product, revenue stream, regulatory outcome, or other specified event. The accounting depends on the rights transferred, the company’s continuing involvement and obligations, recourse provisions, and the mechanics of fixed and contingent payments. A transaction described commercially as a sale, revenue participation arrangement, or other form of monetization may nonetheless require liability accounting when the company retains substantive risks or obligations associated with the underlying cash flows. 

When liability accounting applies, the subsequent measurement model depends on the nature of the obligation and the applicable accounting guidance. Certain arrangements are accounted for using an effective interest method or other amortized-cost approach, while others may require recurring fair value measurement. Accordingly, measurement may depend on product revenue forecasts, probability-weighted milestones, contractual caps or floors, payment timing, and the expected term of the arrangement. Changes in clinical results, regulatory developments, launch timing, pricing, reimbursement, competition, or commercial forecasts may require the liability and related expense to be remeasured. Disclosures should explain the nature and significant terms of the arrangement, the applicable accounting policy, the balance sheet and income statement effects, significant judgments and estimation uncertainty, and relevant liquidity or cash flow implications. When fair value measurement applies, the company should also consider the required valuation technique, input, hierarchy, and sensitivity disclosures. 

Life sciences companies also frequently enter into collaborative arrangements in which the parties actively participate in a joint operating activity and are exposed to significant risks and rewards that depend on the activity’s commercial success. Those arrangements require an evaluation under ASC 808 Collaborative Arrangements, including whether a unit of account is within ASC 606 Revenue from Contracts with Customers.

Fair Value and Valuation Governance 

Financing structures may require valuation at inception, at each reporting date, and/or upon modification or settlement. Management remains responsible for the valuation and should be able to support both the assumptions and period-over-period changes in the resulting values. Outputs should generally remain consistent when the company’s facts and expectations have not changed; when they do change, the model should reflect the underlying business developments, and the effect should be documented. Assumptions should also be reconciled, or differences explained, across board-approved plans, financing forecasts, stock compensation valuations, impairment analyses, and going-concern assessments. 

Valuation conclusions may receive from regulators, particularly when recent security issuances could indicate “cheap stock” or when valuation affects stock-based compensation expense, gains or losses on derivative instruments, or interest expense arising from debt discount amortization. In September 2026, the SEC staff issued Statement on Fair Value Measurement and Disclosure Considerations for Private Assets reminding registrants that fair value measurements for private assets require rigorous application of FASB Accounting Standards Codification (ASC) 820 Fair Value Measurement, robust valuation processes, and transparent disclosures regarding significant judgments, assumptions, and valuation risks.

Contemporaneous Technical Accounting Analysis 

For an experienced finance organization, the objective is not simply to produce an accounting memorandum at closing. The analysis should establish a supportable conclusion and an operating framework for the instrument’s full lifecycle

The process should also reconcile the legal documents, capitalization records, closing statement, board approvals, and valuation models. This is particularly important when several instruments are executed together or when subsequent amendments alter the economics described in the original agreement. 

How CBIZ Can Help 

Financing transactions require coordinated analysis across technical accounting, valuation, tax, legal documentation, and financial reporting. CBIZ Advisory works with life sciences companies to evaluate proposed terms, identify accounting and valuation implications, develop supportable conclusions, and establish processes for subsequent reporting. Addressing these matters during structuring can provide management and the board with a clearer view of the transaction’s full economic and financial reporting impact before capital is committed. Connect with one of our professionals for more information.

Author’s note: The accounting treatment of a financing instrument depends on its specific contractual terms and the company’s facts and circumstances. Companies should consult their accounting advisors early in the negotiation process to evaluate the financial reporting implications before executing a transaction.